Details for Patent: 10,016,396

Which drugs does patent 10,016,396 protect, and when does it expire?

Patent 10,016,396 protects PRECEDEX and is included in one NDA.

This patent has fifty-one patent family members in thirty-five countries.

Summary for Patent: 10,016,396

Patent landscape, scope, and claims:

Title:	Dexmedetomidine premix formulation
Abstract:	The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Inventor(s):	Roychowdhury; Priyanka (Foster City, CA), Cedergren; Robert A. (Libertyville, IL)
Assignee:	HOSPIRA, INC. (Lake Forest, IL)
Application Number:	15/444,932
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 10,016,396

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-002	Mar 13, 2013	AP	RX	Yes	Yes	10,016,396		Y
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-003	Mar 13, 2013	AP	RX	Yes	Yes	10,016,396		Y

International Family Members for US Patent 10,016,396

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	089673
Argentina	117001
Australia	2013201069
Brazil	112013008005